[go: up one dir, main page]

MX2016017001A - Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine. - Google Patents

Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine.

Info

Publication number
MX2016017001A
MX2016017001A MX2016017001A MX2016017001A MX2016017001A MX 2016017001 A MX2016017001 A MX 2016017001A MX 2016017001 A MX2016017001 A MX 2016017001A MX 2016017001 A MX2016017001 A MX 2016017001A MX 2016017001 A MX2016017001 A MX 2016017001A
Authority
MX
Mexico
Prior art keywords
acemetacin
predictive
acematacine
multiparticulated
release system
Prior art date
Application number
MX2016017001A
Other languages
Spanish (es)
Other versions
MX381036B (en
Inventor
Romero Medina Silvia
Romero Castello Samuel
Parra Cervantes Patricia
Saul SOLORZA CAMACHO Karim
Soto Vazquez Ramon
Juarez Lopez Raul
Original Assignee
Productos Maver S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Productos Maver S A De C V filed Critical Productos Maver S A De C V
Priority to MX2016017001A priority Critical patent/MX381036B/en
Publication of MX2016017001A publication Critical patent/MX2016017001A/en
Publication of MX381036B publication Critical patent/MX381036B/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica estable para la administración oral que comprende acemetacina. La acemetacina se encuadra en dos gránulos, donde un primer gránulo se encuentra diseñado para liberar la acemetacina de manera inmediata en un medio de disolución adecuado y el segundo gránulo se encuentra diseñado para proporcionar una liberación de acemetacina de manera predictiva, donde dichos gránulos se encuentran en una misma unidad de dosificación la cual es una cápsula. La composición farmacéutica estable con acemetacina es útil para el tratamiento de trastornos asociados a la inflamación y al dolor.The present invention relates to a stable pharmaceutical composition for oral administration comprising acemetacin. Acemetacin is framed in two granules, where a first granule is designed to release acemetacin immediately in a suitable dissolution medium and the second granule is designed to provide a release of acemetacin in a predictive manner, where said granules are found in the same dosage unit which is a capsule. The stable pharmaceutical composition with acemetacin is useful for the treatment of disorders associated with inflammation and pain.

MX2016017001A 2016-12-19 2016-12-19 Multiparticulate biphasic release system with modified bioavailability prediction of acemetacin. MX381036B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2016017001A MX381036B (en) 2016-12-19 2016-12-19 Multiparticulate biphasic release system with modified bioavailability prediction of acemetacin.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016017001A MX381036B (en) 2016-12-19 2016-12-19 Multiparticulate biphasic release system with modified bioavailability prediction of acemetacin.

Publications (2)

Publication Number Publication Date
MX2016017001A true MX2016017001A (en) 2017-10-06
MX381036B MX381036B (en) 2025-03-12

Family

ID=60296206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017001A MX381036B (en) 2016-12-19 2016-12-19 Multiparticulate biphasic release system with modified bioavailability prediction of acemetacin.

Country Status (1)

Country Link
MX (1) MX381036B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199246A1 (en) * 2018-04-13 2019-10-17 Santa Farma İlaç Sanayi̇ A.Ş. A sustained release formulation comprising acemetacin with bimodal in vitro release

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199246A1 (en) * 2018-04-13 2019-10-17 Santa Farma İlaç Sanayi̇ A.Ş. A sustained release formulation comprising acemetacin with bimodal in vitro release

Also Published As

Publication number Publication date
MX381036B (en) 2025-03-12

Similar Documents

Publication Publication Date Title
CL2019000431A1 (en) Tetrahydro-pyrido [3,4-b] indoles estrogen receptor modulators and uses thereof. (divisional application 201700814)
MX2018008021A (en) Methods and compositions for the treatment of seizure-related disorders.
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
MA38399A1 (en) Formulation in tablet form, useful for treating acute heart failure and chronic heart failure
JOP20180025A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2019012757A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, INCLUDING ENZALUTAMIDE.
CY1118057T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
CR20110704A (en) COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
MX390461B (en) METHODS AND COMPOSITIONS PARTICULARLY FOR THE TREATMENT OF ATTENTION DEFICIT DISORDER
EA201590797A1 (en) PREPARATIONS WITH THE MODIFIED PROBE RELEASE
MX2020004107A (en) DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USE THEREOF.
BR112017022846A2 (en) tamper-proof fixed dose combination that provides rapid release of two different particle drugs
EA201690974A1 (en) HYDROMORPHONE AND NALOXONE FOR THE TREATMENT OF PAIN AND OPIOID-INITIATED INTESTINAL DYSFUNCTION SYNDROME
MA39447B1 (en) Pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016017001A (en) Multiparticulated biphasic release system with enhanced bioavailability predictive of acematacine.
MX391191B (en) EXTENDED-RELEASE COMPOSITIONS OF ONAPRISTONE AND METHODS.
EA201591603A1 (en) NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES
BR112017022335A2 (en) tamper evident fixed dose combination that provides rapid release of two drugs from particles and matrix
BR112017022855A2 (en) tamper-proof fixed dose combination providing rapid release of two drugs from particles and one powder
BR112017022856A2 (en) tamper-proof fixed dose combination that provides rapid release of two drugs from particles
CY1120749T1 (en) PHARMACEUTICAL DOSAGE FORMS
EA201290378A1 (en) COMPOSITIONS CONTAINING NESTEROIDIC ANTI-INFLAMMATORY MEDICINES
BR112018069440A2 (en) oral dosage form
MX386932B (en) PROCESS FOR SOLID FORMULATIONS OF MESALAZINE.
PE20151431A1 (en) CONTROLLED-RELEASE LORAZEPAM FORMULATIONS